Article Text

Download PDFPDF
NIDA Names Deputy Director

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Wilson Compton, MD, MPE, has been appointed the Deputy Director of the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health. Dr. Compton is a recognized expert on the causes and prevention of drug abuse. He has served as Director of the NIDA’s Division of Epidemiology, Services and Prevention Research since 2002 and has served as a member of the DSM-5 Task Force and the Substance Use Disorders Workgroup for the past five years.

In his new role, Dr. Compton will continue to provide leadership for studies designed to assess the impact of new tobacco regulations. The study is jointly sponsored by NIDA and the Food and Drug Administration’s Center for Tobacco Products, and is expected to include more than 50,000 individuals in the U.S. who are age 12 years and older. The study will collect survey data and biological assessments of tobacco exposures, risk factors and health outcomes from participants.

Dr. Compton earned his undergraduate degree from Amherst College. He completed his MD and residency training in psychiatry at Washington University. Prior to joining NIDA, he served as Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis and was Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. In October 2013, he was recognized as a recipient of the Health and Human Services Secretary’s Award for Meritorious Service.

Study Shows Low-Intensity Therapy Effective for Burkitt Lymphoma

The National Institutes of Health (NIH) announced that results from a trial conducted by its National Cancer Institute (NCI) showed low-intensity chemotherapy regimens to be effective in the treatment of adult patients with Burkitt lymphoma. According to the announcement, patient long-term survival rates were upwards of 90 percent following the treatment. This is in contrast to the standard treatment of high-dose chemotherapy, which …

View Full Text